Leiman D, Jové M, Spahn GR, et al. - In this analysis, the three phase 3 registration studies for sufentanil sublingual tablet (SST) 30 mcg were assessed to report on the healthcare professional global assessment (HPGA) and patient global assessment (PGA) scores and the adverse event (AE) profile by age, body mass index (BMI), gender, and race. The HPGA/PGA analyses were performed including a total of 283 patients treated with SST 30 mcg for moderate-to-severe acute pain following surgery or in the emergency department (ED). The safety evaluation was performed including a total of 323 patients. Per findings, SST 30 mcg was highly rated by both healthcare professionals and patients across the demographic subgroups, with the majority of patients not experiencing any adverse event related to SST 30 mcg. Findings overall yield support for using sublingual sufentanil in all adult patients, irrespective of age, BMI, gender, or race for the treatment of moderate-to-severe acute pain.